Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults With Clinically Significant, Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder

Next Previous
Trial Profile

Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults With Clinically Significant, Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jun 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lisdexamfetamine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Shire

Most Recent Events

  • 17 May 2013 Data will be presented at the American Psychiatric Association (APA) 166th Annual Meeting, according to a Shire media release.
  • 07 Jun 2012 Results presented at the 28th International Congress of Collegium Internationale Neuro Psychopharmacologicum.
  • 06 Jun 2012 Quality of life effects presented at the 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top